<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320579">
  <stage>Registered</stage>
  <submitdate>13/08/2010</submitdate>
  <approvaldate>23/08/2010</approvaldate>
  <actrnumber>ACTRN12610000695000</actrnumber>
  <trial_identification>
    <studytitle>Parathyroid gland size and responsiveness to cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism</studytitle>
    <scientifictitle>Parathyroid gland size and responsiveness to cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CRG020800134 (Cochrane Renal Group)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hemodialysis patients with secondary hyperparathyroidism</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cinacalcet hydrochloride, 25 mg once daily, given orally, for 52 weeks. The doses were increased to the next sequential daily dose in the series 25, 50, 75, and 100 mg after at least a 3-week interval if their intact parathyroid hormone was &gt;180 pg/ml at the previous study visit, unless serum calcium was &lt;8.4 mg/dl.</interventions>
    <comparator>Results were compared with historical controls who had been treated with traditional therapy alone, including phosphate binders and vitamin D sterols. Historical data were derived from patients who met the same eligibility criteria as trial participants and had undergone ultrasonography twice at an interval of 1 year between 2000 and 2008.</comparator>
    <control>Historical</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of patients with a mean intact parathyroid hormone &lt;180 pg/ml, as evaluated by the Elecsys assay, during the efficacy-assessment phase.</outcome>
      <timepoint>After 52-weeks of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with a &lt;30% reduction from baseline in intact parathyroid hormone, as evaluated by the Elecsys assay.</outcome>
      <timepoint>After 52-weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in calcium, phosphorus, and intact parathyroid hormone, as evaluated by the Elecsys assay.</outcome>
      <timepoint>After 52-weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in parathyroid gland volume, as evaluated by ultrasonography.</outcome>
      <timepoint>After 52-weeks of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Receiving maintenance dialysis for at least 16 weeks
2. Serum intact parathyroid hormone &gt;300 pg/mL
3. Corrected serum calcium &gt;9.0 mg/dL</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>History of parathyroidectomy or an unstable medical condition during the previous 30 days.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>75</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Japan</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Kobe University School of Medicine</primarysponsorname>
    <primarysponsoraddress>7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017</primarysponsoraddress>
    <primarysponsorcountry>Japan</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Kidney Foundation</fundingname>
      <fundingaddress>2-1-11 Koraku, Bunkyo-ku, Tokyo, 112-0004</fundingaddress>
      <fundingcountry>Japan</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Konan Hospital</sponsorname>
      <sponsoraddress>1-5-16 Kamokogahara, Higashinada-ku, Kobe, 658-0064</sponsoraddress>
      <sponsorcountry>Japan</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Sumiyoshigawa Hospital</sponsorname>
      <sponsoraddress>5-6-7 Konan-cho, Higashinada-ku, Kobe, 658-0084</sponsoraddress>
      <sponsorcountry>Japan</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Chibune Kidney and Dialysis Clinic</sponsorname>
      <sponsoraddress>3-1-11 Tsukuda, Nishiyodogawa-ku, Osaka, 555-0001</sponsoraddress>
      <sponsorcountry>Japan</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Akebono Clinic</sponsorname>
      <sponsoraddress>5-1-1 Shirafuji, Kumamoto, 861-4112</sponsoraddress>
      <sponsorcountry>Japan</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Sumiyoshi Clinic Hospital</sponsorname>
      <sponsoraddress>193-97 Sumiyoshicho, Mito, 310-0844</sponsoraddress>
      <sponsorcountry>Japan</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study was twofold: (1) to elucidate whether parathyroid gland size could be used as an indicator of response to cinacalcet therapy and (2) to examine whether cinacalcet reduces parathyroid gland volume in patients with secondary hyperparathyroidism.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Kobe University School of Medicine</ethicname>
      <ethicaddress>7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017</ethicaddress>
      <ethicapprovaldate>1/01/2008</ethicapprovaldate>
      <hrec>643</hrec>
      <ethicsubmitdate>1/10/2007</ethicsubmitdate>
      <ethiccountry>Japan</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Masafumi Fukagawa</name>
      <address>Division of Nephrology and Kidney Center, Kobe University School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan</address>
      <phone>+81 78 382 6500</phone>
      <fax>+81 78 382 6509</fax>
      <email>fukagawa@med.kobe-u.ac.jp</email>
      <country>Japan</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Masafumi Fukagawa</name>
      <address>Division of Nephrology and Kidney Center, Kobe University School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan</address>
      <phone>+81 78 382 6500</phone>
      <fax>+81 78 382 6509</fax>
      <email>fukagawa@med.kobe-u.ac.jp</email>
      <country>Japan</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Masafumi Fukagawa</name>
      <address>Division of Nephrology and Kidney Center, Kobe University School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan</address>
      <phone>+81 78 382 6500</phone>
      <fax>+81 78 382 6509</fax>
      <email>fukagawa@med.kobe-u.ac.jp</email>
      <country>Japan</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>